Ardelyx says Xphozah now available in the US; shares rise

Ardelyx

06/11/2023 14:17

** Shares of drugmaker Ardelyx  ARDX.O  rise 2.2% to $4.10
premarket 
    ** Co says Xphozah, its drug to treat high phosphate levels
in patients with chronic kidney disease, is now available for
shipment to partner pharmacies in the U.S. 
    ** The drug received FDA's approval last month
    ** Excess phosphorus can remove calcium from bones and other
parts of the body, which in turn can cause brittle bones, joint
pain, muscle cramps and itchy skin
    ** Up to last close, shares up 41.1% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))